In the present study, we reported a patient with locally advanced HER2-positive colon cancer who achieved pCR to four cycles of neoadjuvant chemotherapy combined with trastuzumab and pertuzumab, while experiencing only mild drug-related adverse events. The gene discussed is ERBB2; the disease is malignant colon neoplasm.